Company Fortrea Holdings Inc.

Equities

FTRE

US34965K1079

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Fortrea Holdings Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:14:01 2024-05-24 EDT			5-day change	1st Jan Change
25.66 ^USD	-0.14%		-6.46%	-26.16%

05-23	Some of the biggest splits in Corporate America	RE
05-21	The latest transactions by star managers

Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customersâ needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.

Number of employees: 17,730

USD in Million	2022	Weight	2023	Weight	Delta
Clinical Services 91.3 %	2,825	91.3 %	2,840	91.3 %	+0.50%
Enabling Services 8.7 %	271	8.7 %	270	8.7 %	-0.44%

USD in Million	2022	Weight	2023	Weight	Delta
North America 53.5 %	1,673	54.0 %	1,664	53.5 %	-0.54%
Europe 26.6 %	842	27.2 %	828	26.6 %	-1.71%
Other 19.9 %	582	18.8 %	618	19.9 %	+6.24%

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	89,400,000	89,282,131 ( 99.87 %)	0	99.87 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 16.62 %	14,854,021	16.62 %	540 M $
Vanguard Fiduciary Trust Co. 11.09 %	9,913,921	11.09 %	360 M $
Sessa Capital IM LP 7.131 %	6,375,000	7.131 %	232 M $
Starboard Value LP 6.864 %	6,136,000	6.864 %	223 M $
Starboard Value LP 5.931 %	5,302,000	5.931 %	193 M $
Boston Partners Global Investors, Inc. 4.406 %	3,938,584	4.406 %	143 M $
STATE STREET CORPORATION 3.511 %	3,138,805	3.511 %	114 M $
AllianceBernstein LP 3.449 %	3,083,666	3.449 %	112 M $
Gates Capital Management, Inc. 2.653 %	2,371,628	2.653 %	86 M $
Beck, Mack & Oliver LLC 2.649 %	2,368,212	2.649 %	86 M $

Fortrea Holdings, Inc.

8 Moore Drive

27709, Durham

+877 495 0816

http://fortrea.com/

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.7 USD

Average target price

33.71 USD

Spread / Average Target

+31.18%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
FORTREA HOLDINGS INC.	-26.16%	2.3B
MODERNA, INC.	+69.68%	62.86B
IQVIA HOLDINGS INC.	-0.63%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+14.70%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.41%	18.9B
BIO-TECHNE CORPORATION	+4.73%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.05%	12.27B
MEDPACE HOLDINGS, INC.	+28.11%	12.07B

Other Biotechnology & Medical Research